Navigation Links
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Date:3/10/2011

PARIS and TARRYTOWN, N.Y., March 10, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).  The data showed that adding aflibercept to the chemotherapy drug docetaxel did not meet the pre-specified criteria for the primary endpoint of improvement in overall survival compared with a regimen of docetaxel plus placebo (HR=1.01, CI: 0.868 to 1.174).  The addition of aflibercept to docetaxel demonstrated activity as measured by key secondary endpoints of the study: progression free survival (PFS) (HR=0.82, CI: 0.716 to 0.937) and an overall objective response rate (ORR) of 23.3% in the aflibercept arm compared to 8.9 percent in the placebo arm.

The treatment emergent adverse events (AEs) on the aflibercept arm with an incidence that was 10 percent greater than the control arm were stomatitis, weight decrease, hypertension, epistaxis and dysphonia. Grade 3 or 4 AEs that occurred at a frequency of at least 5 percent in patients who received aflibercept were fatigue, stomatitis, disease progression, hypertension, febrile neutropenia, dyspnea, neutropenia, and asthenia.  AEs leading to treatment discontinuation occurred in 27.2 percent of patients in the aflibercept arm compared to 14.6 percent in the placebo arm.  The types and frequencies of AEs reported in the aflibercept treatment arm were generally consistent with those reported in previous studies with anti-VEGF agents.  

The companies will conduct a detailed analysis of the efficacy and safety results of the VITAL study.  Full results will be presente
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi-aventis Stands Behind the Safety of Lantus(R)
4. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
7. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
8. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
9. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
10. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
11. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015   Mayo Clinic and ... the next generation of wearable biosensors designed to fight ... this technology will be game-changer. These patch biosensors may ... James Levine, M.D., Ph.D. , a Mayo Clinic ... and can be integrated into the care people receive." ...
(Date:3/4/2015)... , March 4, 2015  Results of the ... Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin Detection ... session at the 32 nd Annual Miami Breast ... conducted by Moshe Papa , MD, FACS, Professor ... Tel Aviv University, reports an analysis of MarginProbe,s efficiency ...
(Date:3/4/2015)... 4, 2015  Bayer HealthCare today announced that ... accepted the company,s Biologics License Application (BLA) for ... is seeking FDA approval of the investigational compound, ... hemophilia A in children and adults. ... therapies to hemophilia A patients who need them," ...
Breaking Medicine Technology:Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 2Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 3New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3
... Laboratories, L.C. and Intercell AG (VSE; "ICLL") ... of Romark,s antiviral drug, nitazoxanide, in combination ... (HCV) vaccine, IC41, during the first half ... (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO) Intercell,s vaccine ...
... Oct. 21 IDEV Technologies, Incorporated (IDEV), an innovative ... medical technologies, today announced another step in the implementation ... treating patients with peripheral vascular disease with the addition ... The initial uses of the newly introduced 180mm and ...
Cached Medicine Technology:Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 2Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 3Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 4Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 5IDEV Technologies Launches Additional Products in Europe 2
(Date:3/4/2015)... 04, 2015 FDA’s New Inspection Approach:, ... Webinar**, March 24, 2015 — 1:30 p.m. – 3:00 ... know within four hours of an inspection whether a ... on their “good” list, they’ll merely ask for reassurance ... is on the “bad” list, the manufacturer must get ...
(Date:3/4/2015)... the growing influence of movies, television, video games and the ... combined with the increasingly frantic lifestyle of modern parents, it ... with what kids are into these days. It seems that ... basis. , The same is also true for drugs and ... discreetly talk about them, are constantly changing. These tips put ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Vancouver ... recently received two awards in the prestigious Vancouver ... on February 27, 2015. The company secured third ... place in the “Best Registered Massage Therapist” category. ... community newspapers in Canada, The Vancouver Courier is ...
(Date:3/4/2015)... 2015 State officials have awarded $82,500 ... of Public Health at Georgia State University, to support ... by Georgia’s Division of Family and Children Services (DFCS) ... Call Center. , The 1-800-CHILDREN Helpline is a ... and referral services that promote the wellbeing of children ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The popular ... of their new L-Style Revolution™ Program. The customized program ... and women of all health and fitness levels to ... goals faster than traditional methods. , “We’re really proud ... customized plans based on award winning techniques to help ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2
... Manuel Uribe Garza, thought to be the world's fattest man, had weighed ... been able to shed in just over a year as much as ... ,Seven fully grown men in all, standing in a line. That ... said to have gone out of his body! No-one knows for sure ...
... Haven, Conn. Yale Cancer Center is proud to announce the ... WNPR Connecticut Public Radio. Beginning on National Cancer Survivors Day ... to 6:30 p.m. on Sunday evenings and feature the latest ... and Ken Miller, M.D. , ,Cancer Answers is ...
... killed six people and affected 32 in a tribal-dominated Orissa ... ,All the deaths took place in Koraput district. The victims ... ,Two people from the Paraja and Sirimunda village, ... May 20 and 21, while four more succumbed later, chief ...
... the brain could help treat people who are suffering ... responding to traditional treatment. ,Thomas Schlaepfer, professor ... Germany and associate professor of psychiatry and mental health ... and his team are examining the prospects of deep ...
... developing world to look for new initiatives and programmes targeting ... many nations in the African continent are hard pressed for ... ,Like elsewhere in the third world, visitors to Zambia ... of persons walking aimlessly along the roads, talking to themselves ...
... and Onyx Pharmaceuticals, Inc. today announced that Nexavar(R) ... with hepatocellular carcinoma (HCC), or primary liver ... were presented at the 43rd annual meeting of ... ,The international, Phase 3, placebo-controlled Sorafenib HCC ...
Cached Medicine News:Health News:Worlds Heaviest Man Loses Weight Thanks to Monitored Dieting 2Health News:Yale Cancer Center Answers: A New Weekly Radio Progam on WNPR 2Health News:Implanting Electrodes in the Brain Could Help Treat Severe Depression 2Health News:Zambia Trying Hard to Tackle Crisis in Mental Health Care 2Health News:Nexavar Significantly Extends Survival of Liver Cancer Patients 2
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
Remote Control Vision Tester Can Administer Basic,Distance Vision Tests in Less Than 2 Minutes....
... Increase profitability ... time with simple ... be administered by ... in,less than 5 ...
Vectograms are the standard for vision training. They are available in fixed or variable,styles to accommodate unlimited base-in and base-out training. Each vectogram,includes one pair,of standard 3-...
Medicine Products: